MedTrace Logo

Pharmacogenetic Effect on the Pharmacodynamics of Glibenclamide

NCT01242137 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2010-11-16

No results posted yet for this study

Summary

Glibenclamide is metabolized by the hepatic enzyme P450 CYP2C9 to less active form. Polymorphism of this enzyme demonstrated clinical significance when examined on other drugs from the sulfonylurea drug family, to whom Glibenclamide is included.

The investigators assumption is that patients with less active alleles of the enzyme may show lower dose requirements of the drug for glycemic control, when compared to patients homozygotes to wild-type alleles.

Conditions

Sponsors & Collaborators

  • Assaf-Harofeh Medical Center

    lead OTHER_GOV

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31

Countries

  • Israel

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01242137 on ClinicalTrials.gov